Whether these new therapeutic strategies improve MPN treatment in the future or not, research into HSPs and the PD-1/PD-L1 axis will provide a better understanding of MPN pathogenesis and pave the way for new therapeutic strategies for all types of hematologic malignancies. Here, PDCD1 is linked to myeloproliferative neoplasm.